Table 4 The anticoagulants involved in the TDA events of 107 patients
Involved ACs | Nr. of patients | Proportion |
|---|---|---|
Rivaroxaban+Dalteparin | 43 | 40.1% |
Apixaban+ Dalteparin | 40 | 37.3% |
Dabigataran+ Dalteparin | 7 | 6.5% |
Edoxaban+ Dalteparin | 5 | 4.6% |
Liquemin+ Rivaroxaban | 3 | 2.8% |
Liquemin+Apixaban | 2 | 1.8% |
Liquemin+ Dalteparin | 2 | 1.8% |
Edoxaban+Heparin | 1 | 0.9% |
Liquemin+Dabigatran | 1 | 0.9% |
Apixaban+rivaroxaban | 1 | 0.9% |
apixaban+Arixtra | 1 | 0.9% |
Marcoumar+Liquemin+Dalteparin | 1 | 0.9% |